180 related articles for article (PubMed ID: 36456116)
1. Elimination of Axillary-Lymph-Node Metastases in a Patient With Invasive Lobular Breast Cancer Treated by First-line Neo-adjuvant Chemotherapy Combined With Methionine Restriction.
Kubota Y; Han Q; Masaki N; Hozumi C; Hamada K; Aoki Y; Obara K; Tsunoda T; Hoffman RM
Anticancer Res; 2022 Dec; 42(12):5819-5823. PubMed ID: 36456116
[TBL] [Abstract][Full Text] [Related]
2. [
Kubota Y; Sato T; Han Q; Hozumi C; Morinaga S; Mizuta K; Tsunoda T; Hoffman RM
In Vivo; 2024; 38(1):253-258. PubMed ID: 38148095
[TBL] [Abstract][Full Text] [Related]
3. Rapid Reduction of CEA and Stable Metastasis in an
Kubota Y; Han Q; Morinaga S; Tsunoda T; Hoffman RM
In Vivo; 2023; 37(5):2134-2138. PubMed ID: 37652473
[TBL] [Abstract][Full Text] [Related]
4. Long-term Stable Disease in a Rectal-cancer Patient Treated by Methionine Restriction With Oral Recombinant Methioninase and a Low-methionine Diet.
Kubota Y; Han Q; Hamada K; Aoki Y; Masaki N; Obara K; Tsunoda T; Hoffman RM
Anticancer Res; 2022 Aug; 42(8):3857-3861. PubMed ID: 35896248
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
[TBL] [Abstract][Full Text] [Related]
6. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer.
Kuerer HM; Newman LA; Buzdar AU; Hunt KK; Dhingra K; Buchholz TA; Binkley SM; Ames FC; Feig BW; Ross MI; Hortobagyi GN; Singletary SE
Am J Surg; 1998 Dec; 176(6):502-9. PubMed ID: 9926779
[TBL] [Abstract][Full Text] [Related]
7. Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrence.
Kilbride KE; Lee MC; Nees AV; Cimmino VM; Diehl KM; Sabel MS; Hayes DF; Schott AF; Kleer CG; Chang AE; Newman LA
Ann Surg Oncol; 2008 Nov; 15(11):3252-8. PubMed ID: 18784961
[TBL] [Abstract][Full Text] [Related]
8. Sentinel lymph node mapping following neoadjuvant chemotherapy for breast cancer.
Brady EW
Breast J; 2002; 8(2):97-100. PubMed ID: 11896755
[TBL] [Abstract][Full Text] [Related]
9. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.
Mamounas EP; Anderson SJ; Dignam JJ; Bear HD; Julian TB; Geyer CE; Taghian A; Wickerham DL; Wolmark N
J Clin Oncol; 2012 Nov; 30(32):3960-6. PubMed ID: 23032615
[TBL] [Abstract][Full Text] [Related]
10. Pathologic tumor response of invasive lobular carcinoma to neo-adjuvant chemotherapy.
Joh JE; Esposito NN; Kiluk JV; Laronga C; Khakpour N; Soliman H; Catherine Lee M
Breast J; 2012; 18(6):569-74. PubMed ID: 23034096
[TBL] [Abstract][Full Text] [Related]
11. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.
Kuerer HM; Sahin AA; Hunt KK; Newman LA; Breslin TM; Ames FC; Ross MI; Buzdar AU; Hortobagyi GN; Singletary SE
Ann Surg; 1999 Jul; 230(1):72-8. PubMed ID: 10400039
[TBL] [Abstract][Full Text] [Related]
12. Sentinel lymph node biopsy in patients with operable breast cancer treated with neoadjuvant chemotherapy.
Rebollo-Aguirre AC; Gallego-Peinado M; Menjón-Beltrán S; García-García J; Pastor-Pons E; Chamorro-Santos CE; Ramos-Font C; Salamanca-Ballesteros A; Llamas-Elvira JM; Olea-Serrano N
Rev Esp Med Nucl Imagen Mol; 2012; 31(3):117-23. PubMed ID: 21676504
[TBL] [Abstract][Full Text] [Related]
13. Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy.
Schneider J; Gonzalez-Roces S; Pollán M; Lucas R; Tejerina A; Martin M; Alba A
Breast Cancer Res; 2001; 3(3):183-91. PubMed ID: 11305953
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant therapy approaches to breast cancer: should taxanes be incorporated?
Perez EA
Curr Oncol Rep; 2003 Jan; 5(1):66-71. PubMed ID: 12493153
[TBL] [Abstract][Full Text] [Related]
15. Palbociclib with letrozole as second-line neo-systemic therapy after failure of neo-adjuvant chemotherapy for luminal type breast cancer: A case report.
Jung SU; Jung M; Choi JH; Jeon CW
Medicine (Baltimore); 2021 Apr; 100(14):e25175. PubMed ID: 33832078
[TBL] [Abstract][Full Text] [Related]
16. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer.
Schneeweiss A; Marmé F; Ruiz A; Manikhas AG; Bottini A; Wolf M; Sinn HP; Mansouri K; Kennedy L; Bauknecht T
Ann Oncol; 2011 Mar; 22(3):609-617. PubMed ID: 20732932
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
[TBL] [Abstract][Full Text] [Related]
19. Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
Mavroudis D; Matikas A; Malamos N; Papakotoulas P; Kakolyris S; Boukovinas I; Athanasiadis A; Kentepozidis N; Ziras N; Katsaounis P; Saloustros E; Georgoulias V;
Ann Oncol; 2016 Oct; 27(10):1873-8. PubMed ID: 27502729
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
Mackey JR; Pieńkowski T; Crown J; Sadeghi S; Martin M; Chan A; Saleh M; Sehdev S; Provencher L; Semiglazov V; Press MF; Sauter G; Lindsay M; Houé V; Buyse M; Drevot P; Hitier S; Bensfia S; Eiermann W
Ann Oncol; 2016 Jun; 27(6):1041-1047. PubMed ID: 26940688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
